Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Layla vs myRocky

Layla
Graded #101

Higher grade

vs+19.500000000000007
myRocky
Graded #487

Lower grade

The verdict

Layla takes it — 70.9/100 to 51.4/100.

Layla grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLayla +32
66
34
Dose & formulationLayla +43
96
53
Clinical oversightLayla +12
76
64
Labs & monitoringEven
52
52
FulfillmentmyRocky +5
65
70
Contract termsLayla +14
55
41
Layla · left barmyRocky · right bar

The numbers

MetricLaylamyRocky
WeighScore70.9/10051.4/100
GradeCC
Scorecard rank#101#487
Semaglutide$237/mo (all doses, compounded)Not disclosed
Tirzepatide$199/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesInjection only
Layla

Graded #101 · C

Strengths

  • Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
  • Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
  • Quiz-based intake with fast three to five day shipping

Where it loses points

  • Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
  • States served are not published on the site
  • Support phone line uses a UK format, and the compounding pharmacy is not named
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard